Earlier appears better for immunotherapy in melanoma
Source: Nature Medicine, March 2023
For patients with advanced, resectable melanoma, treatment with pembrolizumab before as well as after surgery led to improved outcomes — without additional toxicity.
Patients with resectable melanoma may benefit from adjuvant immunotherapy with pembrolizumab to help prevent recurrence after surgery. Mechanistic studies and animal models suggest that the addition of neoadjuvant treatment may enhance this benefit, by stimulating earlier proliferation of anti-tumor T cells in the tumor microenvironment.